We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Fusion Antibodies Ltd (FAB) ORD GBP0.04

Sell:6.80p Buy:7.20p 0 Change: No change
Market closed Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6.80p
Buy:7.20p
Change: No change
Market closed Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6.80p
Buy:7.20p
Change: No change
Market closed Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

Contact details

Address:
Springbank Industrial Estate
1 Springbank Road
BELFAST
BT17 0QL
United Kingdom
Telephone:
+44 (028) 90432800
Website:
https://fusionantibodies.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 19 November 2024 19/11/24
AGM 08 October 2024 08/10/24
Annual report 12 September 2024 12/09/24
Final results 12 September 2024 12/09/24
Final results 05 September 2024 05/09/24
Trading Announcement 04 July 2024 04/07/24
General meeting 05 March 2024 05/03/24

General stock information

EPIC:
FAB
ISIN:
GB00BDQZGK16
Market cap:
£6.72 million
Shares in issue:
95.95 million
Sector:
Health Care Equipment & Services
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Adrian Kinkaid
    Chief Executive Officer, Executive Director
  • Stephen Smyth
    Interim Chief Financial Officer and Company Secretary, Executive Director
  • Richard Buick
    Chief Scientific Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.